Yolcu ES - Search Results

1

Engineering donor lymphocytes with Fas ligand protein effectively prevents acute graft-versus-host disease.

Shrestha P, Turan A, Batra L, Gulen AE, Sun Z, Tan H, Askenasy N, Shirwan H, Yolcu ES. Shrestha P, et al. Among authors: yolcu es. Blood Adv. 2023 May 23;7(10):2181-2195. doi: 10.1182/bloodadvances.2022008495. Blood Adv. 2023. PMID: 36780582 Free PMC article.

2

Facilitating cells: Translation of hematopoietic chimerism to achieve clinical tolerance.

Ildstad ST, Leventhal J, Wen Y, Yolcu E. Ildstad ST, et al. Chimerism. 2015 Apr 3;6(1-2):33-9. doi: 10.1080/19381956.2015.1130780. Epub 2016 Jan 8. Chimerism. 2015. PMID: 26745761 Free PMC article.

3

Stem cells as tools in regenerative therapy for retinal degeneration.

Enzmann V, Yolcu E, Kaplan HJ, Ildstad ST. Enzmann V, et al. Arch Ophthalmol. 2009 Apr;127(4):563-71. doi: 10.1001/archophthalmol.2009.65. Arch Ophthalmol. 2009. PMID: 19365041 Free PMC article. Review.

4

Intrathymic immune regulation with donor class I allopeptides leads to the development of immunoregulatory cells that maintain tolerance to cardiac allografts.

Shirwan H, Mhoyan A, Yolcu E, Ibrahim S. Shirwan H, et al. Transplant Proc. 2001 Feb-Mar;33(1-2):80. doi: 10.1016/s0041-1345(00)01912-6. Transplant Proc. 2001. PMID: 11266712 No abstract available.

5

Autoimmune responses regulate alloimmunity for prolonged cardiac allograft survival.

Yolcu E, Fang J, Shirwan H. Yolcu E, et al. Transplant Proc. 2001 Feb-Mar;33(1-2):93. doi: 10.1016/s0041-1345(00)01920-5. Transplant Proc. 2001. PMID: 11266721 No abstract available.

6

Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection.

Yolcu ES, Askenasy N, Singh NP, Cherradi SE, Shirwan H. Yolcu ES, et al. Immunity. 2002 Dec;17(6):795-808. doi: 10.1016/s1074-7613(02)00482-x. Immunity. 2002. PMID: 12479825 Free article.

7

Cardiac allograft acceptance after localized bone marrow transplantation by isolated limb perfusion in nonmyeloablated recipients.

Askenasy N, Yolcu ES, Shirwan H, Wang Z, Farkas DL. Askenasy N, et al. Among authors: yolcu es. Stem Cells. 2003;21(2):200-7. doi: 10.1634/stemcells.21-2-200. Stem Cells. 2003. PMID: 12634416

8

Display of Fas ligand protein on cardiac vasculature as a novel means of regulating allograft rejection.

Askenasy N, Yolcu ES, Wang Z, Shirwan H. Askenasy N, et al. Among authors: yolcu es. Circulation. 2003 Mar 25;107(11):1525-31. doi: 10.1161/01.cir.0000064893.96179.7e. Circulation. 2003. PMID: 12654611

9

Predominant expression of the Th2 response in chronic cardiac allograft rejection.

Mhoyan A, Wu GD, Kakoulidis TP, Que X, Yolcu ES, Cramer DV, Shirwan H. Mhoyan A, et al. Among authors: yolcu es. Transpl Int. 2003 Aug;16(8):464-73. doi: 10.1007/s00147-003-0590-6. Epub 2003 Apr 24. Transpl Int. 2003. PMID: 12712237

10

Prevention of chronic rejection with immunoregulatory cells induced by intrathymic immune modulation with class I allopeptides.

Shirwan H, Mhoyan A, Kakoulidis TP, Yolcu ES, Ibrahim S. Shirwan H, et al. Among authors: yolcu es. Am J Transplant. 2003 May;3(5):581-9. doi: 10.1034/j.1600-6143.2003.00052.x. Am J Transplant. 2003. PMID: 12752314 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

90 results

Search Page

Filters